
Spinraza access agreement extended
More children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with Spinraza after NICE today (3 July) published amended draft guidance following a proposal for extending the terms of the managed access agreement (MAA) between NHS England and Biogen for funding it.